Latest
Risk Factors for Recurrent Venous Thromboembolism in Patients With Sickle Cell Disease
Combination Therapy May Improve Outcomes in Patients With Chronic Lymphocytic Leukemia
Impaired Immunity May Be Intrinsic to Diamond-Blackfan Anemia
Hemolysis, Inflammation, and Iron Overload Characterize Congenital Hemolytic Anemias
Clinical Outcomes in Philadelphia-Negative ALL With Inotuzumab Ozogamicin Plus Chemotherapy
The Cost of Cancer Treatment: Financial Toxicity in Acute Leukemia
Diagnostic Utility of Bleeding Assessment Tool for Identifying Platelet Function Disorders
Immunoglobulin Lambda Translocations Suggest Inferior Prognosis in Newly Diagnosed Multiple Myeloma
Caplacizumab Associated With Improved Outcomes in Acquired Thrombotic Thrombocytopenic Purpura
Decreased Relapse, Mortality Rates With Rituximab in Acquired Thrombotic Thrombocytopenic Purpura
Tumor Lysis Syndrome in Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax
Autologous Stem Cell Transplantation Outcomes in Patients With Peripheral T-Cell Lymphomas
Featured Content
Autologous Stem Cell Transplantation Challenged by Emerging Pharmacotherapies in Multiple Myeloma
Proteasome inhibitors and immunomodulatory drugs have demonstrated improvements in survival and response in patients with multiple myeloma.
Muscle Complaints Are a Frequent Side Effect of TKI Use in CML, but What Causes Them?
Many CML patients on TKI treatment report muscle complaints, but there has been little work to find out why. A new study sought to find out more about the nature of these complaints and to undercover a biological mechanism to explain them.
Navigating Cancer Communication on Twitter
Twitter is increasingly being used by oncologists as a tool to communicate advancements in in the treatment of cancer. What could go wrong?
A Changing Landscape: The Future of Treatment for Acute Myeloid Leukemia
Advances in treatment options for acute myeloid leukemia may replace currently accepted induction regimens as the standard of care.
ASCO/ASH Guideline Update for Cancer-Associated Anemia Management With Erythropoiesis-Stimulating Agents
Treatment with erythropoietin-stimulating agents may yield improved hematopoietic responses and reduce the need for red blood cell transfusions.
